Top

Published in:

Open Access 01-09-2018 | Educational Review

Thrombotic microangiopathy following haematopoietic stem cell transplant

Authors: Eleanor G. Seaby, Rodney D. Gilbert

Published in: Pediatric Nephrology | Issue 9/2018

Abstract

Thrombotic microangiopathy is a potentially lethal complication of haematopoietic stem cell (bone marrow) transplantation. The pathophysiology is incompletely understood, although endothelial damage appears to be central. Platelet activation, neutrophil extracellular traps and complement activation appear to play key roles. Diagnosis may be difficult and universally accepted diagnostic criteria are not available. Treatment remains controversial. In some cases, withdrawal of calcineurin inhibitors is adequate. Rituximab and defibrotide also appear to have been used successfully. In severe cases, complement inhibitors such as eculizumab may play a valuable role. Further research is required to define the pathophysiology and determine both robust diagnostic criteria and the optimal treatment.

Daly A, Xenocostas A, Lipton J (2002) Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 30:709–715CrossRefPubMed

Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL (2013) Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122:2003–2007CrossRefPubMedPubMedCentral

De Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay J-O, Neven B, Moussi J, Simon L (2015) Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99:1953–1959

Holler E, Kolb H, Hiller E, Mraz W, Lehmacher W, Gleixner B, Seeber C, Jehn U, Gerhartz H, Brehm G (1989) Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 73:2018–2024PubMed

Atkinson K, Biggs J, Hayes J, Ralston M, Dodds A, Concannon A, Naidoo D (1983) Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol 54:59–67CrossRefPubMed

Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP (2015) A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29:191–204CrossRefPubMed

Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J (2014) Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 12:565–573PubMed

Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L (2014) Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20:518–525CrossRefPubMed

Tsai H-M, Lian EC-Y (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMedPubMedCentral

10.

Batts E, Lazarus H (2007) Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 40:709–719CrossRefPubMed

11.

Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J (2014) Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124:645–653CrossRefPubMedPubMedCentral

12.

Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S (2005) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11:571–575CrossRefPubMed

13.

Pettitt A, Clark R (1994) Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14:495–504PubMed

14.

Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM, Goulden N, Oakhill A, Pamphilon DH, Steward CG (2001) The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 113:58–64CrossRefPubMed

15.

Laskin BL, Goebel J, Davies SM, Jodele S (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathy. Blood 118:1452–1462CrossRefPubMed

16.

Arai Y, Yamashita K, Mizugishi K, Watanabe T, Sakamoto S, Kitano T, Kondo T, Kawabata H, Kadowaki N, Takaori-Kondo A (2013) Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19:1683–1689CrossRefPubMed

17.

Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC, Davies SM, Jodele S (2013) Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 96:217–223CrossRefPubMedPubMedCentral

18.

Lerner D, Dandoy C, Hirsch R, Laskin B, Davies S, Jodele S (2014) Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy. Bone Marrow Transplant 49:862–863CrossRefPubMed

19.

Chappell M, Keeling D, Prentice H, Sweny P (1988) Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation? Bone Marrow Transplant 3:339–347PubMed

20.

Fortin MC, Raymond MA, Madore F, Fugère JA, Pâquet M, St-Louis G, Hébert MJ (2004) Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin–sirolimus combination. Am J Transplant 4:946–952CrossRefPubMed

21.

Stavrou E, Lazarus HM (2010) Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis 2:e2010033CrossRefPubMedPubMedCentral

22.

Zeigler Z, Shadduck R, Nemunaitis J, Andrews D, Rosenfeld C (1995) Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 15:247–253PubMed

23.

Martinez MT, Bucher C, Stussi G, Heim D, Buser A, Tsakiris D, Tichelli A, Gratwohl A, Passweg J (2005) Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 36:993–1000CrossRefPubMed

24.

Seaby EG, Pengelly RJ, Ennis S (2015) Exome sequencing explained: a practical guide to its clinical application. Brief Funct Genomics 15:374–384CrossRefPubMed

25.

Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, Lane A, Meller J, Medvedovic M, Chen J (2016) The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 127:989–996CrossRefPubMedPubMedCentral

26.

Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK, Bigelow CL, Frangoul HA, Hardy CL, Bredeson C (2009) Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1543–1554CrossRefPubMedPubMedCentral

27.

Legendre CM, Licht C, Muus P, Greenbaum L, Babu S, Bedrosian C, Bingham C, Cohen D, Delmas Y, Douglas K (2013) Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med 368:2169–2181CrossRefPubMed

28.

Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A (2004) Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 10:484–493CrossRefPubMed

29.

Carmona A, Díaz-Ricart M, Palomo M, Molina P, Pino M, Rovira M, Escolar G, Carreras E (2013) Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus–sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant 19:1439–1445CrossRefPubMed

30.

Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, Rapoport AP, Cottler-Fox M, Tricot G, Ruehle K, Meisenberg B (2003) Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion (Paris) 43:78–84CrossRef

31.

Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR (2009) Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 4:345–353CrossRefPubMedPubMedCentral

32.

Cooke KR, Jannin A, Ho V (2008) The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 14:23–32CrossRefPubMed

33.

Robson M, Côte I, Abbs I, Koffman G, Goldsmith D (2003) Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 3:324–327CrossRefPubMed

34.

Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ (2013) The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica 98:526–532CrossRefPubMedPubMedCentral

35.

Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW (2014) Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124:1372–1377CrossRefPubMedPubMedCentral

36.

Rotz SJ, Dandoy CE, Davies SM (2017) ST2 and endothelial injury as a link between GVHD and microangiopathy. N Engl J Med 376:1189–1190CrossRefPubMed

37.

Belford A, Myles O, Magill A, Wang J, Myhand RC, Waselenko JK (2004) Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation. Am J Hematol 76:156–162CrossRefPubMed

38.

Murer L, Zacchello G, Bianchi D, Dall'Amico R, Montini G, Andreetta B, Perini M, DOSSI EC, Zanon G, Zacchello F (2000) Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 11:1132–1137PubMed

39.

Rahbar A, Söderberg-Nauclér C (2005) Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol 79:2211–2220CrossRefPubMedPubMedCentral

40.

Takahashi H, Hanano M, Wada K, Tatewaki W, Niwano H, Shibata A, Tsubouchi J, Nakano M, Nakamura T (1991) Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 38:174–177CrossRefPubMed

41.

Cohen H, Bull H, Seddon A, Enayat M, Hill F, Woolf N, Machin S (1989) Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol 43:207–214CrossRefPubMed

42.

Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J (1997) Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 89:1224–1234PubMed

43.

Matsuda Y, Hara J, Osugi Y, Tokimasa S, Fujisaki H, Takai K, Ohta H, Kawa-Ha K, Okada S (2001) Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. Bone Marrow Transplant 27:977–982CrossRefPubMed

44.

Hasler P, Giaglis S, Hahn S (2016) Neutrophil extracellular traps in health and disease. Swiss Med Wkly 146:w14352PubMed

45.

Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, Lohmeyer J, Preissner KT (2012) Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 7:e32366CrossRefPubMedPubMedCentral

46.

Fuchs TA, Hovinga JAK, Schatzberg D, Wagner DD, Lämmle B (2012) Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 120:1157–1164CrossRefPubMedPubMedCentral

47.

Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, Resink TJ (2010) Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett 584:3193–3197CrossRefPubMed

48.

Wang H, Wang C, Zhao MH, Chen M (2015) Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol 181:518–527CrossRefPubMedPubMedCentral

49.

Ricklin D, Cines DB (2013) TMA: beware of complements. Blood 122:1997–1999CrossRefPubMedPubMedCentral

50.

Dandoy CE, Davies SM, Hirsch R, Chima RS, Paff Z, Cash M, Ryan TD, Lane A, El-Bietar J, Myers KC (2015) Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy. Biol Blood Marrow Transplant 21:113–118CrossRefPubMed

51.

El-Bietar J, Warren M, Dandoy C, Myers KC, Lane A, Wallace G, Davies SM, Jodele S (2015) Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21:1994–2001CrossRefPubMedPubMedCentral

52.

Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, Sawa M, Murata M, Nishiwaki S, Oba T (2009) Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 44:43–49CrossRefPubMed

53.

Staykov D, Schwab S (2011) Posterior reversible encephalopathy syndrome. J Intensive Care Med 27:11–24CrossRefPubMed

54.

Fugate JE, Rabinstein AA (2015) Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 14:914–925CrossRefPubMed

55.

Uderzo C, Jodele S, El Missiry M, Ciceri F, Bacigalupo A, Corbacioglu S (2014) Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when? J Bone Marrow Res 2:152

56.

Mulay S, Kreuter JD, Bryant SC, Elliott MA, Hogan WJ, Winters JL, Gastineau DA (2015) Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant. J Clin Apher 30:147–153CrossRefPubMed

57.

Kennedy G, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S (2010) Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 45:699–704CrossRefPubMed

58.

Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, Davies SM (2013) Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion (Paris) 53:661–667CrossRef

59.

Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444–464CrossRefPubMed

60.

Ostronoff M, Ostronoff F, Calixto R, Florencio R, Florencio M, Domingues M, Maior AS, Sucupira A, Tagliari C (2007) Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant 39:649–651CrossRefPubMed

61.

Corti P (2002) Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 29:542–543CrossRefPubMed

62.

Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM (2016) Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22:307–315CrossRefPubMed

63.

Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, Wallace G, Teusink-Cross A, Davies SM (2016) Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant 22:1337–1340CrossRefPubMedPubMedCentral

Title: Thrombotic microangiopathy following haematopoietic stem cell transplant
Authors: Eleanor G. Seaby
Rodney D. Gilbert
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 9/2018
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-017-3803-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thrombotic microangiopathy following haematopoietic stem cell transplant

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2018

Rhabdomyolysis-associated acute kidney injury: Answers

Submandibular lymphadenopathy in a child post-renal transplant—“What lies beneath?!”: Questions

Rhabdomyolysis-associated acute kidney injury: Questions

Induction prednisone dosing for childhood nephrotic syndrome: how low should we go?

Submandibular lymphadenopathy in a child post-renal transplant—“What lies beneath?!”: Answers

Regenerative medicine in kidney disease: where we stand and where to go